Search Results
Nov 11, 2025, 09:00 ET Lexogen honored as one of Austria's Top Innovative Companies 2026 by Statista and trend. magazine
pursued a clear mission: to help scientists explore how genes work by developing advanced technologies to analyze RNA, the molecule that reveals gene activity. Their complete solutions for RNA and transcriptome analysis are used worldwide by researchers. These tools support both fundamental
More news about: LEXOGEN
Nov 11, 2025, 09:00 ET Lexogen honored as one of Austria's Top Innovative Companies 2026 by Statista and trend. magazine
pursued a clear mission: to help scientists explore how genes work by developing advanced technologies to analyze RNA, the molecule that reveals gene activity. Their complete solutions for RNA and transcriptome analysis are used worldwide by researchers. These tools support both fundamental
More news about: LEXOGEN
Nov 11, 2025, 09:00 ET Complete Genomics Highlights Clinical Research Sequencing Solutions and Partnerships at AMP 2025
predict immunotherapy response in melanoma. Augusta University: Analytical validation of a 1,080-gene oncology panel using the DNBSEQ-T1+ and G400 sequencers with integrated iCare reporting. ABL Diagnostics:
More news about: Complete Genomics
Nov 11, 2025, 09:00 ET Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
modification & cloning, PCR, isothermal amplification, reverse transcription, quantitative real-time PCR, and in vitro transcription, widely used in gene synthesis, molecular diagnostics, biomedical research, and other fields. About Sanyou Bio
More news about: Sanyou Bio
Nov 11, 2025, 08:30 ET Exploring Polycystic Kidney Disease Clinical Trials and New Treatments, Upcoming Webinar Hosted by Xtalks
available.2 Men and women are equally at risk for this inherited disorder, and about 90% of PKD cases are ADPKD, meaning only one copy of the abnormal gene, either PKD1 or PKD2, is needed to cause the disease. Globally, ADPKD affects approximately 12 million people3 and is the most common cause
More news about: Xtalks
Nov 11, 2025, 05:09 ET MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI Tech Co., Ltd.
Nov 11, 2025, 04:40 ET MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI Tech Co., Ltd.
Nov 11, 2025, 04:23 ET uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
investors. On November 3, 2025, uniQure issued a press release concerned a pre-Biologics License Application (BLA) meeting with the FDA about AMT-130, its gene therapy for Huntington's disease (HD). According to the Company, it "believes that the FDA currently no longer agrees that data from the Phase I/II
More news about: DJS Law Group LLP
Nov 10, 2025, 20:30 ET QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Nov 10, 2025, 16:05 ET INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Hemophilia Global Forum. This technology aims to address some of the shortcomings of conventional therapeutic protein replacement treatments including gene therapy approaches. General CorporateINOVIO remains focused on financial discipline and directing
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 15:45 ET Ancient Genes May Explain Why Heart Disease Is So Common Today
The researchers turned to the evolutionary concept of antagonistic pleiotropy — that one gene can serve two purposes, beneficial early in life but detrimental later. "If a gene boosts fertility or survival through child-rearing years but promotes heart disease decades later, it would
More news about: Memorial Health Services
Nov 10, 2025, 12:24 ET TEDCO's Maryland Innovation Initiative Announces Recent Company Formation and Technology Assessment Awardees
assessment: Enhancing DLD diagnosis for bilingual children Justin Hanes - Non-viral brain-penetrating gene therapy for effective treatment of Parkinson's Disease "MII is proud to bring innovation from lab to market,"
More news about: TEDCO
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
New data from Ascend's R&D team demonstrate up to 3-fold increase in AAV yields, supporting greater efficiency and scalability across gene therapy programs. MUNICH, Nov. 10, 2025
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
New data from Ascend's R&D team demonstrate up to 3-fold increase in AAV yields, supporting greater efficiency and scalability across gene therapy programs. MUNICH, Nov. 10, 2025
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend dévoile des activateurs propriétaires qui augmentent significativement les rendements en AAV sans compromis sur la qualité
développement et de fabrication sous contrat spécialisée dans la mise au point et la production de thérapies avancées de qualité et rentables, du niveau du gène au niveau conforme aux bonnes pratiques de fabrication. Ascend a été lancée au début de 2023, à la suite de l'acquisition des actifs de fabrication
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 10:50 ET ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
agreement supports both Dyadic's internal product pipeline and the customized production strains we develop for our partners. By integrating CRISPR-based gene editing into our development workflow, we can boost strain performance, efficiency, and adaptability, delivering greater value across the life sciences,
More news about: ERS Genomics
Nov 10, 2025, 10:00 ET Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions
Geneseeq Technology Inc., a global precision oncology company, today announced its PanTRKare™NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit has received marketing authorization from China's National Medical Products Administration (NMPA). The assay is approved as a companion
More news about: Geneseeq Technology Inc.
Nov 10, 2025, 10:00 ET MS NOW AND ACCUWEATHER® INK MULTI-YEAR DEAL FOR WEATHER COVERAGE
source. For more information, contact: Gene Petriello [email protected]
More news about: AccuWeather, Inc.
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
COLOGNE, Germany, Nov. 10, 2025 /PRNewswire/ -- Under the subject "The Evolving Field of Cell and Gene Therapy", Cellex Cell Professionals GmbH hosted an international symposium on November 6, 2025, in Frankfurt/Main. More than 100 participants from Europe,
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
COLOGNE, Germany, Nov. 10, 2025 /PRNewswire/ -- Under the subject "The Evolving Field of Cell and Gene Therapy", Cellex Cell Professionals GmbH hosted an international symposium on November 6, 2025, in Frankfurt/Main. More than 100 participants from Europe,
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Le Symposium Cellex 2025 réunit des experts internationaux pour discuter de l'évolution du domaine de la thérapie cellulaire et génique
COLOGNE, Allemagne, 10 novembre 2025 /PRNewswire/ -- Sous le thème « The Evolving Field of Cell and Gene Therapy » (Un domaine en pleine évolution : la thérapie cellulaire et génique), Cellex Cell Professionals GmbH a organisé un symposium international
More news about: Cellex Cell Professionals
Nov 10, 2025, 07:00 ET Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech
the Cas-SF01 gene editing tool. This collaboration grants Origin long-term access to fully IP-protected gene editing technologies, providing a solid foundation for the Company's future research and development in trait gene editing. It also aims to accelerate the adoption of advanced gene editing technologies
More news about: Origin Agritech Limited
Nov 10, 2025, 03:48 ET Trillion-Dollar Digital Healthcare Transformations Shaped by AI, Quantum and Biotech Breakthroughs at GITEX GLOBAL
Mammoth Biosciences, captured imaginations with his vision of "rewriting the code of life." Demonstrating how AI and CRISPR technologies can accelerate gene-editing therapies, he revealed, "We have programs across liver, muscle, the brain, where we're actively working on curing genetic diseases using
More news about: GITEX
Nov 10, 2025, 03:39 ET Trillion-Dollar Digital Healthcare Transformations Shaped by AI, Quantum and Biotech Breakthroughs at GITEX GLOBAL
Mammoth Biosciences, captured imaginations with his vision of "rewriting the code of life." Demonstrating how AI and CRISPR technologies can accelerate gene-editing therapies, he revealed, "We have programs across liver, muscle, the brain, where we're actively working on curing genetic diseases using
More news about: GITEX
Nov 09, 2025, 03:00 ET Première thérapie mondiale d'édition génique ciblant l'APOC3 pour le traitement de l'hyperlipidémie
multifactorielle. Le syndrome de chylomicronémie familiale est une maladie autosomique récessive rare causée par des mutations bialléliques du gène de la lipoprotéine lipase (LPL) ou d'autres gènes régulateurs clés, avec des TG à jeun ≥ 10 mmol/L (885 mg/dL) et une prévalence mondiale de 1 cas sur
More news about: CorrectSequence Therapeutics